Antonios-Periklis Panagiotopoulos

Mr. Antonios-Periklis Panagiotopoulos

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in Viruses
Verified
Journal Article
Open access
PDF file
Cleo AnastassopoulouCleo Anastassopoulou
Cleo Anastassopoulou
DTDeny Tsakri
Deny Tsakri
APAntonios-Periklis Panagiotopoulos
Antonios-Periklis Panagiotopoulos
CSChrysa Saldari
Chrysa Saldari
Antonia SagonaAntonia Sagona
Antonia Sagona
Athanasios TsakrisAthanasios Tsakris
Athanasios Tsakris
The increasing prevalence of multidrug-resistant (MDR) bacterial infections necessitates the exploration of alternative antimicrobial strategies, with phage therapy emerging as a viable option. However, the effectiveness of naturally occurring phages can be significantly limited by bacterial defense systems that include adsorption blocking, restriction–modification, CRISPR-Cas immunity, abortive infection, and NAD+ depletion defense systems. This review examines these bacterial defenses and their implications for phage therapy, while highlighting the potential of phages’ bioengineering to overcome these barriers. By leveraging synthetic biology, genetically engineered phages can be tailored to evade bacterial immunity through such modifications as receptor-binding protein engineering, anti-CRISPR gene incorporation, methylation pattern alterations, and enzymatic degradation of bacterial protective barriers. “Armed phages”, enhanced with antimicrobial peptides, CRISPR-based genome-editing tools, or immune-modulating factors, offer a novel therapeutic avenue. Clinical trials of bioengineered phages, currently SNIPR001 and LBP-EC01, showcase their potential to safely and effectively combat MDR infections. SNIPR001 has completed a Phase I clinical trial evaluating safety in healthy volunteers, while LBP-EC01 is in Phase II trials assessing its performance in the treatment of Escherichia coli-induced urinary tract infections in patients with a history of drug-resistant infections. As “armed phages” progress toward clinical application, they hold great promise for precision-targeted antimicrobial therapies and represent a critical innovation in addressing the global antibiotic resistance crisis.

6 August 2025 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
Cleo AnastassopoulouCleo Anastassopoulou
Cleo Anastassopoulou
APAntonios-Periklis Panagiotopoulos
Antonios-Periklis Panagiotopoulos
SFStefanos Ferous
Stefanos Ferous
Athanasios TsakrisAthanasios Tsakris
Athanasios Tsakris
Antimicrobial resistance (AMR) poses a severe global health threat, necessitating alternatives to conventional antibiotics, which are increasingly ineffective. Phages play a dual role in both propagating and potentially mitigating AMR. They facilitate AMR dissemination primarily through transduction, with emerging evidence suggesting indirect involvement in conjugation and transformation. Phage–plasmids, a dynamic entity bridging phages and plasmids, have gained increasing attention for their role in AMR evolution. Conversely, phage therapy has demonstrated promise in targeting MDR pathogens and disrupting biofilms through lytic activity and enzymatic degradation. However, challenges, such as phage resistance, host specificity and regulatory constraints, must be addressed to enable widespread clinical implementation. While regulatory frameworks for phage therapy remain underdeveloped in many regions, initiatives such as the EMA workshop in 2015 have sought to establish pathways for regulatory approval, addressing issues related to phage standardization, phage production, quality control, clinical validation and product monitoring. Leveraging the extensive experience of Eastern European countries, where phage therapy has been successfully integrated into medical practice, may accelerate its acceptance in Western healthcare systems. Integrating phages with existing antimicrobial strategies may provide a viable approach to combating AMR. Phages thus connect the biological dots of AMR by contributing to its generation and spread, but possibly also to its resolution, likely in combination with antibiotics.

10 May 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
APAntonios-Periklis Panagiotopoulos
Antonios-Periklis Panagiotopoulos
Antonia SagonaAntonia Sagona
Antonia Sagona
DTDeny Tsakri
Deny Tsakri
SFStefanos Ferous
Stefanos Ferous
Cleo AnastassopoulouCleo Anastassopoulou
Cleo Anastassopoulou
Athanasios TsakrisAthanasios Tsakris
Athanasios Tsakris
As antimicrobial resistance continues to undermine the efficacy of antibiotics, the global medical community is increasingly turning to alternative treatment modalities. Among these, phage therapy has re-emerged as a promising strategy for managing multidrug-resistant bacterial infections. Herein, we present and briefly discuss eight essential attributes of clinically relevant phages for therapy, which may be categorized broadly into virological and pharmacological characteristics. Virological attributes include a broad host range, a strictly lytic life cycle and the ability to manage the emergence of bacterial resistance to phages. Comprehensive genomic and proteomic characterization forms the foundation for selecting and engineering such candidates, ensuring both safety and predictability. From a pharmacological standpoint, phages should ideally show safety across relevant formulations and routes of administration, favorable pharmacokinetics, stability during storage and scalability in manufacturing. Advances in genomic analysis, artificial intelligence-driven phage selection and formulation technologies have further accelerated the translational potential of phage therapy. By systematically addressing each of these critical attributes, this work aims to inform the rational selection and development of therapeutic phages suitable for integration into the clinical practice.

20 April 2025 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
Cleo AnastassopoulouCleo Anastassopoulou
Cleo Anastassopoulou
APAntonios-Periklis Panagiotopoulos
Antonios-Periklis Panagiotopoulos
NSNikolaos Siafakas
Nikolaos Siafakas
Athanasios TsakrisAthanasios Tsakris
Athanasios Tsakris
RNA-binding proteins (RBPs) are essential regulators of cellular RNA processes, including RNA stability, translation, and post-translational regulation. During viral infections, RBPs are key regulators of the viral cycle due to their interaction with both host and viral RNAs. Herein, we initially explore the roles of specific RBP families, namely heterogeneous nuclear ribonucleoproteins (hnRNPs), DEAD-box helicases, human antigen R (HuR), and the eukaryotic initiation factors of the eIF4F complex, in viral RNA replication, translation, and assembly. Next, we examine the potential of these RBPs as host-targeting antivirals against pandemic-prone RNA viruses that have been gaining momentum in recent years. Targeting RBPs could disrupt cellular homeostasis, leading to unintended effects on host cells; however, RBPs have been successfully targeted mainly in anticancer therapies, showcasing that their modulation can be safely achieved by drug repurposing. By disrupting key viral-RBP interactions or modulating RBP functions, such therapeutic interventions aim to inhibit viral propagation and restore normal host processes. Thus, conceivable benefits of targeting RBPs as alternative antiviral strategies include their broad-spectrum activity and potential for combination therapies with conventional antivirals, reduced or delayed resistance development, and concomitant enhancement of host immune responses. Our discussion also highlights the broader implications of leveraging host-directed therapies in an attempt to overcome viral resistance. Finally, we emphasise the need for continued innovation to refine these strategies for broad-spectrum antiviral applications.

25 November 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
APAntonios-Periklis Panagiotopoulos
Antonios-Periklis Panagiotopoulos
Cleo AnastassopoulouCleo Anastassopoulou
Cleo Anastassopoulou
Athanasios TsakrisAthanasios Tsakris
Athanasios Tsakris
JIJohn P A Ioannidis
John P A Ioannidis
The next pandemic may demand faster, more flexible responses with better risk-benefit and cost-benefit ratios than current systems can deliver. During COVID-19, R&D funding allocation strongly favored vaccines over antivirals and regulatory approvals of vaccines far exceeded approvals for antivirals. Moreover, early evidence on antiviral effectiveness was often limited or even misleading. Antivirals may have advantages in early outbreak control, high-risk populations, and settings with delayed vaccine uptake. For future pandemics, we propose a dedicated antiviral agenda to coordinate R&D for broad-spectrum agents, fund phase 2/3 trials for high-severity pathogens, enable rapid manufacturing scale-up for demonstrably effective interventions, and secure equitable global access through tiered pricing, stockpiling, and technology transfer. This platform would fill the critical therapeutic blind spot in existing pandemic vaccine-centric strategies. The proposed approach should ensure transparency, strengthen equity, and provide rigorous evidence for both vaccines and antivirals, dissecting their relative benefits, limitations, complementarity, and cost–benefit.

18 August 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
APAntonios-Periklis Panagiotopoulos
Antonios-Periklis Panagiotopoulos
DTDeny Tsakri
Deny Tsakri
KRKyriaki Ranellou
Kyriaki Ranellou
Cleo AnastassopoulouCleo Anastassopoulou
Cleo Anastassopoulou
Athanasios TsakrisAthanasios Tsakris
Athanasios Tsakris
Seasonal influenza remains a major global public health challenge despite decades of vaccine development, underscoring the need for more effective and adaptable immunization strategies. The recently approved mRNA-1010 vaccine represents a promising advance by applying messenger RNA technology to a pathogen characterized by continuous antigenic drift. Recent Phase 3 clinical trials conducted in support of regulatory review have demonstrated robust immunogenicity and superior protective efficacy against seasonal influenza compared with standard influenza vaccines in adults aged 50 years and older. However, increased reactogenicity, particularly among younger adults, together with the need for continued post-marketing safety surveillance, highlights the balance between enhanced immune responses and tolerability. Beyond seasonal influenza, mRNA-1010 provides a foundation for next-generation respiratory vaccines, including combination formulations targeting influenza, SARS-CoV-2, and respiratory syncytial virus (RSV), while illustrating the broader potential of mRNA vaccine technology. At the same time, challenges related to manufacturing scalability, cost, cold-chain requirements, and global accessibility remain important considerations for widespread implementation. This perspective examines whether mRNA-1010 represents an incremental advance in influenza vaccination or a potential transformative milestone in respiratory immunization, while considering the continuing roles of alternative vaccine platforms in achieving optimal effectiveness, safety, and equitable global access.